Tumor formation was not observed in mice transplanted with one of the two clones of HBp17/FGFBP-1-KO A431 cells in vivo, which confirmed the significant difference in growth in vitro between HBp17/FGFBP-1-KO and WT cells, indicating that HBp17/FGFBP-1 is potentially a potent therapeutic target in SCC/OSCC cells. Here, FGFBP1 is linked to neoplasm.